PledPharma AB (publ) Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
20/06 | Transcript : Egetis Therapeutics AB - Special Call | |
19/06 | Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency | CI |
Sales 2024 * | 60.99M 5.78M 483M | Sales 2025 * | 491M 46.6M 3.89B | Capitalization | 2.04B 193M 16.14B |
---|---|---|---|---|---|
Net income 2024 * | -293M -27.79M -2.32B | Net income 2025 * | 107M 10.15M 848M | EV / Sales 2024 * | 31.7 x |
Net cash position 2024 * | 105M 9.93M 829M | Net cash position 2025 * | 229M 21.68M 1.81B | EV / Sales 2025 * | 3.68 x |
P/E ratio 2024 * |
-6.81
x | P/E ratio 2025 * |
15.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.24% |
Latest transcript on PledPharma AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 16/17/16 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 31/17/31 |
Chief Tech/Sci/R&D Officer | - | 05/22/05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mats Blom
CHM | Chairman | 59 | 01/21/01 |
Director/Board Member | 50 | 01/20/01 | |
Thomas Lönngren
BRD | Director/Board Member | 73 | 01/21/01 |
1st Jan change | Capi. | |
---|---|---|
+20.03% | 126B | |
+23.61% | 118B | |
+23.26% | 27.87B | |
-18.07% | 20.95B | |
-15.13% | 16.92B | |
-14.81% | 16.18B | |
+9.78% | 14.84B | |
-46.10% | 14.79B | |
+52.34% | 14.08B |